On October 25, 2017, another physician, Jerrold Rosenberg, M.D., pleaded guilty to charges related to the plethora of kickback prosecutions emanating from Insys Therapeutics, Inc., and its fentanyl drug, Subsys. Couch and Ruan Sent to Prison In February of this year, I wrote in my post Pain Medicine Doctors Alleged to Have Received $115,000 in […]
Tag: pharmaceutical
As I comment often, the federal Anti-Kickback statute makes it illegal to receive anything of value for the referral of federal health care program patients.
The speed limit’s 70 mph. I’m not going to tell you how fast I’m going, but I’m going with the flow of traffic, which is traveling at a lot more than the speed limit. Would a defense of, “but everyone is speeding” actually work?
A recent article by Joseph Walker in the Saturday/Sunday, Feb. 4-5, 2017, issue of The Wall Street Journal, sheds light on the marketing of opioids, the payment of kickbacks, and the high profits that can be made via their sale through physician owned pharmacies. A review of the related indictment reveals even more. The context […]
If the future of surgery is medicine, then the future of medicines is compounding, the individualization of dosages and drug combinations.
Compounding pharmaceuticals, specific drugs for specific patients, offers tremendous benefit. The problems arise when the benefit is for the prescribing physician. Then, we’re dealing with analyses under the federal Anti-Kickback Statute (AKS), the Stark Law, and their state law counterparts.
I know. In light of tons of illegal profits, complying with the federal anti-kickback law (“AKS”) is a hard sell.
I know. In light of tons of illegal profits, complying with the federal anti-kickback law (“AKS”) is a hard sell. But, it’s easier than a prison cell. And better than paying a $125 million fine.
A physician has been indicted for his role in a compound pharmacy prescription scam that included disguised kickbacks. Lots of lessons here.
If the future of surgery is medicine, then the future of medicines is compounding, the individualization of dosages and drug combinations. Earlier this month, the FDA approved the first 3-D printed drug product, Spritam, developed by Aprecia Pharmaceuticals. The layering process of 3-D printing allows Apecia to tightly package active ingredients in precise dosages. A […]